47th week of 2009 patent applcation highlights part 33 |
Patent application number | Title | Published |
20090285798 | CD4 MIMIC PEPTIDES AND THEIR USES - An isolated peptide comprising the sequence (I): TPA-Asn-Leu-His-Phe-Cys-Gln-Leu-Xaa | 2009-11-19 |
20090285799 | Antibody Antagonists of Interleukin-13 Receptor Alpha1 - Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed. | 2009-11-19 |
20090285800 | Aberrant expression of CKS1 and CKS2 and uses thereof - The present invention is drawn to providing a therapeutic strategy for prostate cancer. In this regard, the present invention demonstrates that elevated expression of Cks1 contributes to tumorigenicity of prostate tumor cells by promoting cell growth and elevated expression of Cks2 protects cells from apoptosis. Accordingly, the present invention discloses methods to diagnose and treat prostate cancer by targeting expression of Cks1 and Cks2 proteins. | 2009-11-19 |
20090285801 | Calcium-Sensing Receptor 2 (CaR2) and Methods for Using - The current disclosure provide a novel human calcium sensing receptor named CaR2 and the nucleotide sequence that encodes the receptor. The disclosure further provides antibodies specific for CaR2. Also disclosed are methods of identifying modulators of the receptor and methods of using the identified modulators to treat calcium receptor mediated conditions. | 2009-11-19 |
20090285802 | HIGHLY CONCENTRATED STABILIZED IGM SOLUTION - The present inventors discovered that stable and highly concentrated IgM solutions can be prepared by using, as an additive, a compound comprising a polyvalent cationic ion, such as magnesium chloride or arginine hydrochloride, to suppress IgM aggregation in solutions. | 2009-11-19 |
20090285803 | ANTI-PirB ANTIBODIES - The present invention relates generally to neural development and neurological disorders. The invention specifically concerns identification of novel modulators of the myelin-associated inhibitory system and various uses of the modulators so identified. | 2009-11-19 |
20090285804 | Anti-ADDLs antibodies and uses thereof - The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. | 2009-11-19 |
20090285805 | Binding molecules - The present invention relates to the manufacture of a diverse repertoire of functional heavy chain-only antibodies that undergo affinity maturation, and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of class-specific heavy chain-only antibodies and to the manufacture and use of multivalent polypeptide complexes with antibody heavy chain functionality, preferably antibody heavy chain binding functionality, constant region effector activity and, optionally, additional effector functions. The present invention also relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge. In particular, the present invention relates to a method for the generation of human antigen-specific, high affinity, heavy chain-only antibodies of any class, or mixture of classes and the isolation and expression of fully functional VH antigen-binding domains. | 2009-11-19 |
20090285806 | Methods and compositions for improving recombinant protein production - Nucleic acid molecules modified to enhance recombinant protein expression, e.g., that of Aβ peptide binding antibodies, and/or to reduce or eliminate mis-spliced and/or intron read-through (IRT) by-products are disclosed. The invention also provides methods for producing Aβ peptide binding antibodies devoid of mis-spliced and/or intron read-through by-products by expression of such nucleic acid molecules under cell culture conditions suitable for recombinant Aβ peptide binding antibody expression. | 2009-11-19 |
20090285807 | Anti-Met Monoclonal Antibody, Fragments and Vectors Thereof, for the Treatment of Tumors and Corresponding Products - Use of a monoclonal antibody directed against the extracellular domain of hepatocyte growth factor is disclosed for the preparation of a medicament for the treatment of tumors and/or metastases and of a diagnostic tool for detecting neoplastic cells as well as vectors comprising at least a portion of the nucleotide sequence encoding the anti-Met monoclonal antibody, products containing the anti-Met monoclonal antibody and/or at least one fragment thereof and at least one kinase inhibitor. | 2009-11-19 |
20090285808 | ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY - The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies. | 2009-11-19 |
20090285809 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES - Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components. | 2009-11-19 |
20090285810 | HUMANIZED ANTI-TGF-BETA ANTIBODIES - Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies. | 2009-11-19 |
20090285811 | ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE GLUCOCORTICOID STEROIDS - The present invention relates to new glucocorticoid steroid modulators of glucocorticoid receptor, pharmaceutical compositions thereof, and methods of use thereof. | 2009-11-19 |
20090285812 | ANTI-PSGL-1 ANTIBODIES AND METHODS OF IDENTIFICATION AND USE - The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for such antibodies and binding fragments thereof and to methods of therapeutic use thereof. | 2009-11-19 |
20090285813 | ANTIBODIES AND METHODS FOR MAKING AND USING THEM - The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic anti-bodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations. | 2009-11-19 |
20090285814 | CD 40 Binding Molecules and CTL Pepetides for Treating Tumors - Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor antigens. Such composition is useful for enhancing the anti-tumor effect of a peptide tumor vaccine, or for otherwise activating CTLs so that the activated CTLs can act against tumorous or infected cells. The CD40 binding molecules can include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) | 2009-11-19 |
20090285815 | IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION - Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins. | 2009-11-19 |
20090285816 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2009-11-19 |
20090285817 | Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene - A mixture comprising at least one inhibitor or suppressor of the expression of a gene and at least one molecule binding to an expression product of said gene. | 2009-11-19 |
20090285818 | Cripto Blocking Antibodies and Uses Thereof - The invention provides Cripto blocking antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and modulate Cripto signaling are provided. Antibodies which bind Cripto and block the interaction between Cripto and ALK4 are provided. Antibodies which bind Cripto and modulate tumor growth are also provided. Antibodies which bind Cripto, modulate signaling, and modulate tumor growth are also provided. Antibodies which bind Cripto, block the interaction between Cripto and ALK4 and modulate tumor growth are provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications. | 2009-11-19 |
20090285819 | METHODS AND COMPOSITIONS FOR TREATING INFLUENZA - Genes relating to resistance to infection by influenza virus are identified. The genes and the gene products (i.e., the polynucleotides transcribed from and polypeptides encoded by the genes) can be used for the prevention and treatment of influenza. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products. | 2009-11-19 |
20090285820 | Methods of Treating Degenerative Disorders With Rac 1B Inhibitor - The invention relates to compositions and methods for treating degenerative disorders. More particularly, the invention relates to methods of treating amyloïd beta peptide-related disorders, particularly Alzheimer's disease, using Rac1b inhibitors. The invention may be used in mammalian subjects, particularly human subjects, at various stages of the disease, including disease onset. The invention also provides methods of producing, identifying, selecting or optimising compounds for use in the treatment of amyloïd beta peptide-related disorders, based on a determination of the ability of a test compound to inhibit Rac1b. | 2009-11-19 |
20090285821 | Campylobacter Pilus Protein, Compositions and Methods - The present disclosure provides coding and amino acid sequences for a | 2009-11-19 |
20090285822 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components. | 2009-11-19 |
20090285823 | GLYCOPEPTIDES DERIVED FROM PANCREATIC STRUCTURES, ANTIBODIES AND APPLICATIONS THEREOF IN DIAGNOSTICS AND THERAPEUTICS - Glycopeptide comprising 1 to 40 repeated C-terminal polypeptides, with 11 amino acids, of BSDL or FAPP, whereby said polypeptides are glycosylated and bear glycosylated epitopes giving rise to a specific immunological reaction with induced antibodies in a patient suffering from type 1 diabetes and/or purified from biological fluids of human or animal origin or recombinant and produced by expression in a standard host cell comprising an enzymatic material necessary for priming a glycosylation, said host cell being genetically modified such as to comprise a gene coding for said polypeptides and a gene coding for one or more enzymes selected from among glycosyltransferases, anti-glycopeptide antibodies and the applications thereof in therapeutics and diagnostics. | 2009-11-19 |
20090285824 | Compositions and methods relating to anti IGF-1 receptor antibodies - The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions. | 2009-11-19 |
20090285825 | NOVEL SNAKE TOXIN - This invention is in the field of snake venom and the invention provides a novel snake toxin protein and nucleic acids encoding the same. Also, provided are various uses and compositions based on the discovery of the novel snake toxin. | 2009-11-19 |
20090285826 | COMBINATION DRUGS COMPRISING VEGF INHIBITOR AND SERINE PROTEASES/THROMBOLYTIC COMPOUNDS FOR TREATING NEOVASCULAR DISORDERS - Pharmaceutical compositions for inhibiting, preventing or treating unwanted angiogenesis/neovascularization, including that of ocular tissues, contain agents that inhibit VEGF in combination with a second therapy, e.g., that elicited by serine proteases/thrombolytic compounds. | 2009-11-19 |
20090285827 | ANTAGONIST ANTIBODIES AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8 ASSOCIATED DISORDERS - The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention. | 2009-11-19 |
20090285828 | Anti-PECAM Therapy for Metastasis Suppression - The invention provides novel compositions, methods, kits, and uses thereof relating to antimetastatic agents useful for treating neoplastic diseases. | 2009-11-19 |
20090285829 | Medicinal Agent and Method for Curing Prostate Diseases - A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to the prostate-specific antigen, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to homeopathic technology. In order to obtain the antibodies, the prostate-specific antigen isolated from the prostatic tissues of cattle or prepared synthetically is employed; a mixture of various, mostly centesimal, homeopathic dilutions is used. The method of treating diseases of the urogenital sphere consists in using activated forms of ultra-low doses of antibodies to prostate-specific antigen prepared by multiple consecutive dilutions and exposure to external factors. | 2009-11-19 |
20090285830 | ANTIBODIES TO LYMPHOTOXIN-ALPHA - The invention provides various antibodies that bind to lymphotoxin-α, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies. | 2009-11-19 |
20090285831 | IMMUNOINTERACTIVE MOLECULES - The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothielial growth factor-B (VEGF-B) or its functional or structural equivalent and inhibit the biological activity of VEGF-B. In particular the present invention relates to deimmunized such as humanized or human antibodies that bind to VEGF-B and inhibit the biological activity of VEGF-B. These antibodies have uses in the treatment or prevention of diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling. The present invention further contemplates a method of modulating diseases associated with perturbations in normal vasculogenesis or angiogenesis or vascular remodelling by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies which bind to VEGF-B and block the biological activity of VEGF-B. Accordingly, a method of screening for inhibitors of the biological activity of VEGF-B is also provided. | 2009-11-19 |
20090285832 | METHODS FOR TREATING SUNITINIB-RESISTANT CARCINOMA AND RELATED BIOMARKERS - A method of determining whether a tumor will be non-responsive to sunitinib therapy including detecting whether IL-8 or MMP12 expression levels in the tumor are elevated as compared to a control, that is, a tumor having elevated IL-8 or MMP12 levels will be non-responsive to sunitinib. Also, a method for inhibiting the proliferation or causing the death of a sunitinib-resistant tumor cell by contacting the cell with an agent that inhibits IL-8 or MMP12 activity and with sunitinib, whereby proliferation of the tumor cell is inhibited or the tumor cell dies. Further, the invention includes compositions and kits that include an IL-8 inhibitor or an MMP12 inhibitor and sunitinib, and related methods of treatment. | 2009-11-19 |
20090285833 | CLOSTRIDIUM BOTULINUM C3 EXOTRANSFERASE COMPOSITIONS AND METHODS FOR TREATING TUMOUR SPREADING - Pharmaceutical compositions, each consisting of a cell-permeable fusion protein conjugate of a polypeptidic cell-membrane transport moiety and a | 2009-11-19 |
20090285834 | NOVEL MEMORY CTL INDUCTION POTENTIATOR - The present invention relates to a memory CTL induction enhancer comprising a combination of substance (b) with substance (a) and/or substance (c), wherein substance (a) is an activator of antigen-presenting cells, substance (b) is an inducer of homeostatic proliferation after induction of lymphopenia, and substance (c) is a suppressor of regulatory T cells. | 2009-11-19 |
20090285835 | Antibodies which bind human CXCR3 - Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments. | 2009-11-19 |
20090285836 | USE OF SALINOSPORAMIDE A TO INHIBIT METASTASIS - The present invention relates to methods and compositions for treating and evaluating metastatic conditions. | 2009-11-19 |
20090285837 | HER2 ANTIBODY COMPOSITION - A composition comprising a main species HER2 antibody that binds to domain II of HER2, and an amino acid sequence variant thereof comprising an amino-terminal leader extension is disclosed. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed. | 2009-11-19 |
20090285838 | USE OF SOLUBLE CD164 IN INFLAMMATION AND AUTOIMMUNE DISORDERS - The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of human CD164, in particular for treating inflammatory and/or autoimmune disorders. | 2009-11-19 |
20090285839 | Antigen uptake receptor for candida albicans on dendritic cells - Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen | 2009-11-19 |
20090285840 | METHODS FOR TREATING PATHOLOGICAL NEOVASCULARIZATION - Provided herein are compositions and methods that inhibit expression of Adam9 gene products, such as ADAM9 mRNA and/or ADAM9 polypeptides, as a therapeutic approach for the treatment of pathological neovascularization and conditions associated with angiogenesis. | 2009-11-19 |
20090285841 | ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF - This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations. | 2009-11-19 |
20090285842 | IMMUNE PRIVILEGED AND MODULATORY PROGENITOR CELLS - Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like. | 2009-11-19 |
20090285843 | EPITOPE SEQUENCES - Disclosed herein are polypeptides, including epitopes, clusters, and antigens. Also disclosed are compositions that include said polypeptides and methods for their use. | 2009-11-19 |
20090285844 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA - A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation. | 2009-11-19 |
20090285845 | Domains And Epitopes Of Meningococcal Protein NMB1870 - ‘NMB1870’ is a known surface protein in | 2009-11-19 |
20090285846 | MUTANTS OF CHOLESTEROL-DEPENDENT CYTOLYSINS AND USES THEREOF - Mutants of cholesterol-dependent cytolysins comprising at least one amino acid substitution in at least one of Loop 1, Loop 2, or Loop 3 of Domain 4, nucleic acids encoding such polypeptide mutants, and compositions and vaccines comprising such polypeptide mutants. | 2009-11-19 |
20090285847 | Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis - Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen | 2009-11-19 |
20090285848 | METHODS AND COMPOSITIONS FOR IMMUNIZING AGAINST PSEUDOMONAS INFECTION - Methods and compositions for inducing an immune response against | 2009-11-19 |
20090285849 | Thiosemicarbazones as anti-virals and immunopotentiators - Novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, as well as novel methods for treating viral infections, including HCV, by administering the compounds and compositions, and novel methods for modulating the immune response by administering the compounds and/or compositions. | 2009-11-19 |
20090285850 | Oral Carotenoid Supplementation Methods for Improving the Health and Appearance of Skin - Provided herein are oral skin care supplements and nutraceutical compositions and methods of use for improving the health and appearance of skin. Also provided are nutraceutical compositions that, when orally consumed will provide nourishment and deliver essential skin health nutrition to the skin. These nutraceutical compositions include omega 3 rich oils, vitamins, lutein, marine collagen and elastin. Also provided is a unique microalgae oral delivery system targeting the health and appearance of skin. | 2009-11-19 |
20090285851 | VACCINE COMPRISING MONOCYTE OR IMMATURE MYELOID CELLS (IMC) WHICH WERE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN - The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with α-galactosylceramide (αGalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent. | 2009-11-19 |
20090285852 | Expression System Incorporating a Capsid Promotor Sequence as an Enhancer of a Cytomegalovirus Promotor - The invention provides a method for enhancing expression of a transgene in a host cell, which includes the steps of inserting a capsid promoter element (Pcap), or a sequence comprising the reverse complement of the capsid promoter element (PcapR), into a mammalian expression cassette upstream (5′) of a cytomegalovirus immediate/early enhancer/promoter region (Pcmv); inserting the transgene into the expression cassette downstream (3′) of the cytomegalovirus immediate/early enhancer/promoter region; inserting a vector containing the expression cassette into the host organism; and causing expression of the transgene. The capsid promoter element (Pcap) is typically from a circovirus, parvovirus or anellovirus. The transgene is typically expressed at a higher level than when expressed by a vector containing the expression cassette without the transcriptional control element. An expression cassette, vector, DNA vaccine, pharmaceutical composition and method of treatment are also claimed. | 2009-11-19 |
20090285853 | Nucleic Acids Encoding Respiratory Syncytial Virus Subgroup B strain 9320 - The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described. | 2009-11-19 |
20090285854 | FROZEN STOCKPILING OF INFLUENZA VACCINES - A problem with stockpiling influenza vaccines is their short shelf life. Storage volume is another problem. The invention prepares and stockpiles bulk vaccine, and the bulk is stored under frozen conditions. Compared to final vaccine, the higher antigen concentration and absence of packaging materials (boxes, vials, etc.) in the bulk means that the storage space requirements are hugely reduced. A process for preparing an influenza vaccine bulk thus comprises the steps of: (a) preparing bulk vaccine antigen from a source of influenza virus; and (b) storing the bulk vaccine prepared in step (a) under frozen conditions. | 2009-11-19 |
20090285855 | RECOMBINANT VACCINE AGAINST JAPANESE ENCEPHALITIS VIRUS (JEV) INFECTION AND A METHOD THEREOF - The present invention relates to a novel recombinant adenovirus (RAdEs) vaccine against Japanese encephalitis virus (JEV) infection, wherein said vaccine produces secretory JEV envelope protein; an effective and superior method of immunization to JEV infection; also, a method of preparing the recombinant RAdEs vaccine. | 2009-11-19 |
20090285856 | HELICOBACTER SPECIES AND CULTIVATION THEREOF - The present invention relates to the isolation and cultivation of “Candidatus | 2009-11-19 |
20090285857 | RECOMBINANT CHIMERIC ANTIGENS FOR DIAGNOSIS AND PREVENTION OF SCRUB TYPHUS - Recombinant chimeric antigens comprising unmodified and modified reactive polypeptide fragments of expressed product of the recombinant 56 kDa proteins of multiple strain of scrub typhus, such as Karp, Kato (Ktr56), Gilliam (Gmr56), and TA763 (TAr56). The invention is useful for detecting prior exposure to a number of strains of scrub typhus, based on the strength of reaction toward the chimeric protein and as a component in vaccine formulations and production of immune globulins for passive prophylaxis and immunity in subjects against heterologous infections. | 2009-11-19 |
20090285858 | PREVENTION OF ALLERGY IN CHILDREN - The present invention relates to a use of bacterial superantigens in the manufacture of a pharmaceutical composition for mucous membrane administration for the prevention of inflammatory disorders in newborn infants, such pharmaceutical compositions, as well as method for prevention of inflammatory disorders. | 2009-11-19 |
20090285859 | Allergenic proteins of natural rubber latex, their production and use in assays - This invention relates to allergenic proteins of natural rubber latex in substantially purified form, their production and their use, together with monoclonal antibodies developed against those allergenic proteins, in assays for the qualitative and quantitative determination of the levels of the allergenic proteins in natural rubber latex or in products made from latex. Assays for identifying and/or quantitating antibodies in blood or blood products that mediate the occurrence of an allergic reaction induced by natural rubber latex are also provided, together with in vivo and in vitro diagnostic tests for detecting hypersensitivity to natural rubber latex and which involve use of the aforesaid allergenic proteins. The invention also provides for the use of the aforesaid allergens as de-sensitising agents in the treatment of latex protein allergy. There is still further provided a method for removing allergenic proteins from latex products. | 2009-11-19 |
20090285860 | Cancer immunotherapy - Method of stimulating an immune response (e.g., to treat cancer) include administering to a subject a composition including dendritic cells incubated with (i) oHSV-infected tumor cells or a composition derived therefrom, or (ii) tumor cells plus oHSV, as well as methods of preparing such compositions, are described. | 2009-11-19 |
20090285861 | Tumor cell-based cancer immunotherapeutic compositions and methods - The present invention is based, in part, on the discovery that immunotherapy using cell-based tumor cells genetically modified to express heat shock proteins is particularly effective in preventing, prognosing and/or treating cancer (e.g., ovarian cancer). Accordingly, the invention relates to compositions, kits, and methods for preventing, prognosing and/or treating cancer (e.g., ovarian cancer). | 2009-11-19 |
20090285862 | METHODS AND COMPOSITION FOR TREATMENT OF INFLAMMATORY PAIN - The present invention relates to the field of pain management, and in particular, the management of inflammatory pain without inducing overt sedation. The present invention features compositions and treatments for inflammatory pain comprising the administration of an amount of an neurokinin (NK) antagonist in combination with a neuronal excitation inhibitor. | 2009-11-19 |
20090285863 | Coating Composition Comprising Starch - The present invention provides a coating composition comprising an aqueous medium and, dispersed therein, starch and a film-forming agent which controls swelling of the starch by the aqueous medium. Formulations comprising the coating composition are also provided. The formulations may be useful in the treatment or diagnosis of colonic disease. | 2009-11-19 |
20090285864 | THERAPEUTIC FORMULATION - The invention provides compositions and formulations comprising catechol and/or acetogenins and various combinations thereof; including various combinations with other ingredients including botanical preparations containing acetogenin, an extract of green tea or a therapeutically active flavanoid contained in green tea; and one or more quinones. The invention includes a pharmaceutical composition including a salt of rhodizonic acid, an OH anion-generating base, a non-toxic acid, a quinone, a salt-containing sulfite, catechol and optionally, an acetogenin and an extract of green tea. The compositions and formulations demonstrate positive effects against a broad variety of cancer, autoimmune diseases, viruses and provides antioxidant protection against peroxyl hydrophilic, peroxyl lipophilic, hydroxyl, peroxynitrite and super oxide radicals. The compositions and formulations can be used for nutritional and nutraceutical uses, and used as dietary supplements. | 2009-11-19 |
20090285865 | Palatable, solid oral formulations for male chemical sterilization - Palatable, solid oral formulations or compositions include at least one bioactive agent capable of chemical sterilization of human and animal males. Depending on the targeted species, the bioactive formulations comprise suitable additives, excipients, water-swellable compositions, and/or processing aids and can be made into uncoated or coated forms to modulate the release profile of the bioactive agents. Among the bioactive agents are zinc compounds and complexes and organic drugs with established pharmacological activities, which are traditionally unrelated to any form of contraception. | 2009-11-19 |
20090285866 | Self-healing polymer compositions - A composition including a film-former and a porous polymeric release system comprising a solvent for the film-former is provided. Also provided is a method of prolonging the physical stability of a film-former on the skin by applying to the skin a self-healing composition containing the film-former and a porous polymeric release system comprising a solvent for the film-former. | 2009-11-19 |
20090285867 | METHOD FOR EXTEMPORANEOUS AND REVERSIBLE CONCENTRATION OF LIPOSOMES - The invention concerns a method for extemporaneous and reversible concentration of liposomes, the mixed liposome-cyclodextrin aggregates obtainable by the method, and uses thereof in the pharmaceutical, diagnostic and cosmetic field. | 2009-11-19 |
20090285868 | Photostable cosmetic compositions comprising dibenzoylmethane/pyrrolidinone compounds - Photostable UV-photoprotecting cosmetic sunscreen compositions contain (a) an effective UV-photoprotecting amount of at least one dibenzoylmethane compound sunscreen, (b) an effective radiation-photostablizing amount of at least one pyrrolidinone compound having the formula (I) below: | 2009-11-19 |
20090285869 | SALT STABLE LECITHIN ORGANOGEL COMPOSITION - A lecithin organogel (“LO”) operates as a transdermal pharmaceutical delivery composition. In particular, the lecithin organogel comprises an internal oil phase containing oil-in-water (“O/W”) and water-in-oil (“W/O”) emulsifiers, and an aqueous phase comprising inorganic and organic hydrocolloids. The lecithin organogel may contain up to 80% additive ingredients, including biocompatible surfactants, nonpolar solvents, saturated fatty alcohols, moisturizers, preservatives or antimicrobials, and chelating agents. | 2009-11-19 |
20090285870 | ANTIFUNGAL/ANTIBACTERIAL AGENT COMPRISING TWO-STEP BAKED SHELL POWDER - An antimold/antibacterial agent characterized by comprising a baked shell powder which is obtained by washing shells with water, drying, roughly crushing, baking the crushed matter in a non-oxidizing atmosphere at a low temperature of 500 to 600° C. and then in the air atmosphere at a medium temperature of 600 to 900° C., and pulverizing the baked shells to preferably an average particle size of 40 μm or less. By the two-step baking treatment, an inorganic composite powder in which a small amount of calcium oxide is scattered in porous calcite-type calcium carbonate can be obtained, and thanks to its porosity and synergetic action between calcium carbonate and calcium oxide, the powder can exhibit excellent and long-lasting antimold/antibacterial effects. | 2009-11-19 |
20090285871 | Disinfectant Wet Wipe - A disinfectant wet wipe that contains a germicidal solution and a nonwoven web material is provided. The germicidal solution includes a peracid and peroxide, which can act synergistically together to be efficacious against pathogens when exposed thereto. To stabilize the solution over a period of time (e.g., during storage), a variety of aspects of the wipe are selectively controlled in accordance with the present invention. For example, the nonwoven web material used in the wipe is formed from a synthetic polymer and is relatively hydrophobic in nature. Without intending to be limited by theory, it is believed that such materials possess a lower reduction potential for peroxides/peracids than cellulosic-based materials. In this manner, significant degradation of the peroxide or peracid contained in the germicidal solution is limited. To improve the wettability of the nonwoven web material, one or more surfactants are also employed in the germicidal solution. Besides improving wettability, the present inventors have surprisingly discovered that certain surfactants may also improve the stability of the solution. | 2009-11-19 |
20090285872 | Amphibious Carrier and Method of Manufacturing - An all weather amphibious carrier and method for manufacturing thereof, for use on land and in water, which includes an adjustable strap system for wearing by a person; a foldable body or member adjustably attachable to the strap system and capable of supporting an infant or child upon folding the member and attaching the member to the strap system; the strap system being made of weather-resistant, synthetic, polymerized rubber, a high-strength, resilient synthetic polymer, and a polymer containing polyurethane; and the foldable body member being made of a weather-resistant, synthetic, polymerized rubber, a synthetic fabric made from a polymer containing polyurethane; and a flexible polyurethane open-cell antimicrobial-coated foam. The unique combination of materials keeps the baby/toddler from becoming sweaty when used for land activities, because the materials breathe. When used in water, rain, and snow, it dries quickly, because the water can pass through the through the body if conventional stitching is used or the body can be completely water-tight by using flatlock, breathable seams. The special quilted design also adds extra support, comfort and security for both care-giver/parent and baby, making this carrier ergonomically sound, both on land and in water. | 2009-11-19 |
20090285873 | IMPLANTABLE MEDICAL DEVICES AND COATINGS THEREFOR COMPRISING BLOCK COPOLYMERS OF POLY(ETHYLENE GLYCOL) AND A POLY(LACTIDE-GLYCOLIDE) - The present invention provides a block copolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same. | 2009-11-19 |
20090285874 | Implantable Devices For Accelerated Healing - Implantable devices (e.g., stent) having a protein patterning or bioactive patterning for accelerated healing and method of forming and using the same are provided. | 2009-11-19 |
20090285875 | Infused Sponge Delivery System - A method for delivering active ingredients to a wet substrate from a flexible, three-dimensional, water-absorbent substrate material comprised of a web of substantially water-insoluble fibers into which is infused a solid anhydrous composition having a melting point of from about 45° C. to about 55° C. said anhydrous composition comprising (i) at least one surfactant selected from the group consisting of cationic quaternary surfactants, anionic surfactants or nonionic surfactants or one multi-lamellar liquid crystal emulsifier system, (ii) at least one fatty alcohol, (iii) at least one emollient selected from the group consisting of cosmetically-acceptable oils, esters and liquid triglycerides, (iv) at least one active ingredient and (v) optionally, a solid cleansing agent having a melting point from about 50° C. to about 70° C. Preferred active ingredients are skincare and haircare actives, including emollients, humectants, conditioning agents, sunscreens and sunblocks, and artificial tanning agents. | 2009-11-19 |
20090285876 | Natural butters reconstituted by transesterification with glycerin and its use in cosmetics applications - The invention provides a composition comprising reaction products from a reaction of a natural butter or natural oil such as shea butter with glycerin in the presence of a basic catalyst and wherein the reaction products retain the unsaponifiable portion of said natural butter or natural oil. The resulting reaction products are self-emulsifiable and are particularly useful in personal care, cosmetic, pharmaceutical, paper and textile applications. | 2009-11-19 |
20090285877 | Percutaneous absorption preparation containing palonosetron - There is provided a percutaneous absorption preparation that has a simple laminated structure and a long shelf life, while maintaining excellent percutaneous absorption for palonosetron. The percutaneous absorption preparation comprises a support and a drug-containing pressure-sensitive adhesive layer formed on at least one side of the support, wherein the drug-containing pressure-sensitive adhesive layer comprises, as essential constituent components, an adhesive base, palonosetron or a pharmaceutically acceptable acid addition salt thereof, and at least one type of fatty alcohol selected from the group consisting of C6-12 straight-chain saturated alcohols, C10-22 straight-chain unsaturated alcohols, C10-22 branched alcohols and C10-15 cyclic alcohols, and the constituent components other than palonosetron or its pharmaceutically acceptable acid addition salt are carboxyl group-free components. | 2009-11-19 |
20090285878 | Compositions and methods for stabilizing liposomal drug formulations - The present invention is directed to liposomal compositions comprising a camptothecin, which are optimized to reduce camptothecin degradation and/or precipitation of camptothecin degradation products in the external medium. The invention further provides improved methods of formulating liposomal camptothecins, kits comprising liposome-encapsulated camptothecins, and methods of using the same to treat a variety of diseases and disorders, including cancer. | 2009-11-19 |
20090285879 | Malaria prime/boost vaccines - Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from | 2009-11-19 |
20090285880 | DRIED RECONSTITUTED VESICLE FORMATION FOR PHARMACEUTICAL APPLICATION - The present invention relates to dried reconstituted vesicle (DRV) compositions and water based formulations thereof, which contain one or more therapeutic agents (e.g. hydrophilic protein). More particularly, it relates to DRVs comprising at least one lipid and a fusion promoting agent which after reconstitution form large multilamellar liposomes encapsulating an active agent in an aqueous phase. | 2009-11-19 |
20090285881 | CATIONIC LIPIDS AND USES THEREOF - Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed. | 2009-11-19 |
20090285882 | Stabilized Liposome Compositions and Related Methods of Use - Liposome compositions and related methods of preparation which can comprise one or a plurality of biopolymer components. | 2009-11-19 |
20090285883 | Identification of gastrointestinal, pancreatic and cancer stem cell markers and methods of use thereof - DCAMKL-1 has been identified as a biomarker for stem cells, as well as cancer stem cells. Methods of detecting the presence of at least one stem cell, methods of isolating stem cells, and methods of inhibiting growth of cancer cells utilizing DCAMKL-1 are disclosed herein. | 2009-11-19 |
20090285884 | Platinum Complexes and Methods of Use - The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro. | 2009-11-19 |
20090285885 | Method of forming a drug nanocarrier having a magnetic shell - The invention discloses the synthesis and manufacturing of a novel core-shell nano-carrier with a drug-containing nanocomposite core surrounding with a single crystalline magnetic iron oxide shell. With a unique core-shell configuration, active agents such as drugs and biomolecules encapsulated in the core with an outer single-crystalline thin iron oxide shell can be perfectly protected from environmental damages and in the meantime, eliminating un-desirable release due to un-controllable diffusion of the active molecules from the nanocapsules during the course of delivery in patient's body, before reaching the disease sites. | 2009-11-19 |
20090285886 | ENHANCED ANTIMICROBIAL ACTIVITY OF PLANT ESSENTIAL OILS - Antimicrobial compositions based on a combination of plant essential oils of enhanced antimicrobial effectiveness are prepared by adding to the combination of at least two plant essential oils, a small but antimicrobial enhancing effective amount of an enhancer selected from the group consisting of polyionic organic enhancers and polyionic inorganic enhancers. One preferred composition it is a mixture of plant essential oils wherein at least one of the oils is oregano oil. | 2009-11-19 |
20090285887 | Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor - A modified release pharmaceutical composition for oral administration comprising plural mini-tablets, comprising a therapeutically effective amount of a Factor Xa inhibitor within a matrix of polymer(s). The mini-tablets are suitably encapsulated within a gelatin capsule. A manufacturing process and method of use are also described. | 2009-11-19 |
20090285888 | DERIVATIVES OF DIHYDROXYPHENYLALANINE - The invention relates to derivatives of dihydroxyphenylalanine, to their synthesis and to pharmaceutical compositions containing said derivatives of dihydroxyphenylalanine. Furthermore, the invention relates to the use of said derivatives of dihydroxyphenylalanine and said pharmaceutical compositions for the treatment and prophylaxis of movement disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, hemiparkinson-hemiatrophy, parkinsonian syndrome, Lewy body disease, frontotemporal dementia, Lytico-Bodig disease (parkinsonism/dementia/amyotrophic lateral sclerosis), striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive atrophy of the globus pallidus, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X-linked dystonia-parkinsonism (Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless legs syndrome, Wilson's disease. | 2009-11-19 |
20090285889 | MODIFIED RELEASE FORMULATIONS OF DIHYDROPYRIDINE COMPOUNDS AND METHODS OF MAKING SAME - The invention relates to a modified release (e.g., extended release) tablet composition for oral administration comprising: (a) a dihydropyridine compound or a prodrug or salt thereof; (b) a first release control agent; (c) a second release control agent; and (d) a third release control agent; wherein said second release control agent has a higher viscosity than said first release control agent. The invention also relates to methods for making such modified release (e.g., extended release) tablet compositions. After tableting, such compositions exhibit a release profile that is approximately zero order without the need of a coating. | 2009-11-19 |
20090285890 | ANTIMICROBIAL PEROXIDASE COMPOSITIONS - The present invention discloses a class of compounds which have an enhancing effect on peroxidase based antimicrobial compositions. The invention relates to pharmaceutical compositions for prolonged topical use comprising enhancing agents such as methoxyphenols and substituted benzylaldehydes. Examples hereof are respectively guaiacol and vanillin. | 2009-11-19 |
20090285891 | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production - Any pharmaceutical preparation for oral administration with controlled release of active ingredient in the small bowel, on the basis of active ingredient carriers provided with at least one active ingredient which are provided with an inner layer to control the release of active ingredient and with a gastro-resistant coating layer disposed thereon, which is characterized in that the inner layer is formed from at least two diffusion layers whose permeability for the diffusing active ingredient decreases from the inside to the outside, and a method for the production thereof, are described. | 2009-11-19 |
20090285892 | METHODS AND SYSTEMS FOR EXPANDING AC133+ CELLS AND DIRECTING DIFFERENTIATION - The invention provides, among other things, methods and systems for expanding CD133+ cells. The invention further provides methods and systems for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides methods and systems for directing differentiation of expanded CD133+ cells. The invention further provides methods and systems for treating a subject with differentiated cells in a subject in need thereof. | 2009-11-19 |
20090285893 | TREATMENT OF HEART FAILURE IN WOMEN - A method is disclosed utilizing an androgen such as testosterone and/or a selective androgen receptor modulator for treating or delaying the further development of heart failure, and other disorders in females including manifestations of heart failure and concomitant cardiovascular and noncardiovascular disorders. | 2009-11-19 |
20090285894 | MICRO-PARTICLES CONTAINING A 3-D POLYMERIC STRUCTURE - Micro-sized particles having a polymeric structure of cells are provided. Also provided is a method of producing micro-sized particles having a polymeric structure comprising: (1) forming a homogenous solution by heating a mixture of a high molecular weight polymer and a low molecular weight material, wherein said low molecular weight material makes up at least about 50% by weight of the homogenous solution, (2) forming a dispersed solution by dispersing the homogenous solution formed in step (1) into an inert material, (3) cooling the dispersed solution to cause the high molecular weight polymer to phase separate from the low molecular weight material, (4) forming solid particles comprised of said low molecular weight material trapped inside a structure of cells of said high molecular weight polymer, and (5) removing the solid particles from the dispersed solution. | 2009-11-19 |
20090285895 | Pharmaceutical Formulation for Regulating the Timed Release of Biologically Active Compounds Based on a Polymer Matrix - A formulation containing a biologically active compound having a structure with hydrogen bonding sites is blended with a polymer having a structure with complementary hydrogen bonding sites, the polymer forming hydrolytic degradation products that promote the release of the biologically active compound from the polymer. | 2009-11-19 |
20090285896 | BIOABSORBABLE POLYESTERAMIDES AND USES THEREOF - Novel biodegradable polyesteramides derived from optionally functionalized diacids and optionally functionalized diamines or from compounds having both optionally functionalized acid and optionally functionalized amine moieties, their preparation, and absorbable surgical articles fabricated therefrom, such as monofilament and multifilament sutures, films, sheets, plates, clips, staples, pins, screws, stents, stent coatings, packaging materials, and other implantable surgical devices, and the like, are described herein. | 2009-11-19 |
20090285897 | REHYDRATABLE THIOLATED POLYSACCHARIDE PARTICLES AND SPONGE - Tissue and other body structures may be protected using a hydrated composition made from free-flowing rehydratable particles or a rehydratable sponge comprising substantially collagen-free dehydrothermally crosslinked thiolated polysaccharide. Rehydration of crosslinked or uncrosslinked polysaccharide particles may be carried out without clumping by dispersing the particles in a biocompatible water-miscible polar dispersant such as ethanol and combining the dispersion with sufficient aqueous solvent for the particles to convert them to a cohesive hydrogel. The hydrated particles or sponge may assist in returning an injured, inflamed or surgically repaired surface to a normal state, e.g., through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or other full or partial restoration of normal function. | 2009-11-19 |